Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.

@article{Nash1999AntiparkinsonianAO,
  title={Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.},
  author={Joanne E. Nash and Michael P Hill and Jonathan Michael Brotchie},
  journal={Experimental neurology},
  year={1999},
  volume={155 1},
  pages={42-8}
}
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved difficult to devise a nondopaminergic therapy with significant antiparkinsonian efficacy when administered as monotherapy. Overactivity of the striatolateral pallidal pathway, the "indirect" striatal output pathway… CONTINUE READING